Department of Pathology, Pamukkale University, Denizli, Turkey.
Department of Pathology, Isparta City Hospital, Isparta/, Turkey.
Indian J Pathol Microbiol. 2021 Jan-Mar;64(1):84-90. doi: 10.4103/IJPM.IJPM_980_19.
Bladder cancer is the ninth most common type of cancer worldwide. We aimed to investigate the relationship between tumor grade, lamina propria invasion, muscularis propria invasion, and lymphovascular invasion and human epidermal growth factor receptor 2 (HER-2), cyclin D1, and alpha-methyl-CoA racemase (AMACR) expressions in bladder cancer.
The study included patients who underwent complete TURBT. In total, 72 cases of bladder cancer diagnosed by two pathologists were selected. AMACR, HER-2, cyclin D1 expressions were detected immunohistochemically.
The study population comprised 80% (57) males and 20% (15) females (mean age, 68 years). Further, 35 cases were noninvasive and 37 invasive urothelial carcinoma and 38 patients had low-grade tumor and 34 high-grade tumor. Intense immunostaining was observed with cyclin D1 for 75% tumors, AMACR for 39%, and HER-2 for 86%. High expressions of cyclin D1 and AMACR were observed in high-grade tumors (P < 0.05 and P < 0.005, respectively). High expression of HER-2 (2 and 3 positive) was found both at low- and high-grade tumors (84% and 88%, respectively).
Cyclin D1, AMACR expressions were found to be significant predictive factors of high-grade tumors. High Her-2 expression in patients with bladder carcinoma may indicate that they are potential targets for treatment. These markers may be important in determining prognosis of tumors and may be valuable for guiding treatment options.
膀胱癌是全球第九大常见癌症。我们旨在研究膀胱癌中肿瘤分级、固有层浸润、肌层浸润和脉管侵犯与人类表皮生长因子受体 2（HER-2）、细胞周期蛋白 D1 和α-甲基辅酶 A 消旋酶（AMACR）表达之间的关系。
本研究纳入了接受完全经尿道膀胱肿瘤切除术（TURBT）的患者。共选择了 72 例经两位病理学家诊断为膀胱癌的患者。采用免疫组织化学法检测 AMACR、HER-2、细胞周期蛋白 D1 的表达。
研究人群中 80%（57 例）为男性，20%（15 例）为女性（平均年龄 68 岁）。进一步分为非浸润性和浸润性尿路上皮癌，其中 35 例为非浸润性，37 例为浸润性；38 例为低级别肿瘤，34 例为高级别肿瘤。75%的肿瘤Cyclin D1 免疫染色强烈，39%的肿瘤 AMACR 免疫染色强烈，86%的肿瘤 HER-2 免疫染色强烈。高级别肿瘤中观察到 Cyclin D1 和 AMACR 的高表达（P < 0.05 和 P < 0.005）。低级别和高级别肿瘤中均发现 HER-2（2 和 3 阳性）高表达（分别为 84%和 88%）。
Cyclin D1、AMACR 的表达被认为是高级别肿瘤的显著预测因子。膀胱癌患者中 HER-2 的高表达可能表明其是潜在的治疗靶点。这些标志物可能对确定肿瘤的预后具有重要意义，并可能对指导治疗选择具有重要价值。
